Radiopharmaceutical for Nuclear Medicine Market Report – Research, Industry Analysis Reports and Market Demands

Global Radiopharmaceutical for Nuclear Medicine Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Radiopharmaceutical for Nuclear Medicine by Type
- 1.3.1 Overview: Global Radiopharmaceutical for Nuclear Medicine Market Size by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Global Radiopharmaceutical for Nuclear Medicine Consumption Value Market Share by Type in 2025
- 1.3.3 Diagnosis Nuclear Medicine
- 1.3.4 Therapeutic Nuclear Medicine
1.4 Classification of Radiopharmaceutical for Nuclear Medicine by Disease
- 1.4.1 Overview: Global Radiopharmaceutical for Nuclear Medicine Market Size by Disease: 2021 Versus 2025 Versus 2032
- 1.4.2 Global Radiopharmaceutical for Nuclear Medicine Consumption Value Market Share by Disease in 2025
- 1.4.3 Technetium-99m
- 1.4.4 Fluorine-18
- 1.4.5 Iodine-123
- 1.4.6 Iodine-131
- 1.4.7 Lutetium-177
- 1.4.8 Other
1.5 Global Radiopharmaceutical for Nuclear Medicine Market by Application
- 1.5.1 Overview: Global Radiopharmaceutical for Nuclear Medicine Market Size by Application: 2021 Versus 2025 Versus 2032
- 1.5.2 Hospital
- 1.5.3 Imaging Center
- 1.5.4 Others
1.6 Global Radiopharmaceutical for Nuclear Medicine Market Size & Forecast
1.7 Global Radiopharmaceutical for Nuclear Medicine Market Size and Forecast by Region
- 1.7.1 Global Radiopharmaceutical for Nuclear Medicine Market Size by Region: 2021 VS 2025 VS 2032
- 1.7.2 Global Radiopharmaceutical for Nuclear Medicine Market Size by Region, (2021-2032)
- 1.7.3 North America Radiopharmaceutical for Nuclear Medicine Market Size and Prospect (2021-2032)
- 1.7.4 Europe Radiopharmaceutical for Nuclear Medicine Market Size and Prospect (2021-2032)
- 1.7.5 Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Size and Prospect (2021-2032)
- 1.7.6 South America Radiopharmaceutical for Nuclear Medicine Market Size and Prospect (2021-2032)
- 1.7.7 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size and Prospect (2021-2032)

2 Company Profiles

3 Market Competition, by Players

3.1 Global Radiopharmaceutical for Nuclear Medicine Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Radiopharmaceutical for Nuclear Medicine by Company Revenue
- 3.2.2 Top 3 Radiopharmaceutical for Nuclear Medicine Players Market Share in 2025
- 3.2.3 Top 6 Radiopharmaceutical for Nuclear Medicine Players Market Share in 2025
3.3 Radiopharmaceutical for Nuclear Medicine Market: Overall Company Footprint Analysis
- 3.3.1 Radiopharmaceutical for Nuclear Medicine Market: Region Footprint
- 3.3.2 Radiopharmaceutical for Nuclear Medicine Market: Company Product Type Footprint
- 3.3.3 Radiopharmaceutical for Nuclear Medicine Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Radiopharmaceutical for Nuclear Medicine Consumption Value and Market Share by Type (2021-2026)
4.2 Global Radiopharmaceutical for Nuclear Medicine Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Radiopharmaceutical for Nuclear Medicine Consumption Value Market Share by Application (2021-2026)
5.2 Global Radiopharmaceutical for Nuclear Medicine Market Forecast by Application (2027-2032)

6 North America

6.1 North America Radiopharmaceutical for Nuclear Medicine Consumption Value by Type (2021-2032)
6.2 North America Radiopharmaceutical for Nuclear Medicine Market Size by Application (2021-2032)
6.3 North America Radiopharmaceutical for Nuclear Medicine Market Size by Country
- 6.3.1 North America Radiopharmaceutical for Nuclear Medicine Consumption Value by Country (2021-2032)
- 6.3.2 United States Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 6.3.3 Canada Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Radiopharmaceutical for Nuclear Medicine Consumption Value by Type (2021-2032)
7.2 Europe Radiopharmaceutical for Nuclear Medicine Consumption Value by Application (2021-2032)
7.3 Europe Radiopharmaceutical for Nuclear Medicine Market Size by Country
- 7.3.1 Europe Radiopharmaceutical for Nuclear Medicine Consumption Value by Country (2021-2032)
- 7.3.2 Germany Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 7.3.3 France Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 7.3.5 Russia Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 7.3.6 Italy Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Radiopharmaceutical for Nuclear Medicine Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Radiopharmaceutical for Nuclear Medicine Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Radiopharmaceutical for Nuclear Medicine Market Size by Region
- 8.3.1 Asia-Pacific Radiopharmaceutical for Nuclear Medicine Consumption Value by Region (2021-2032)
- 8.3.2 China Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 8.3.3 Japan Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 8.3.5 India Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 8.3.7 Australia Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)

9 South America

9.1 South America Radiopharmaceutical for Nuclear Medicine Consumption Value by Type (2021-2032)
9.2 South America Radiopharmaceutical for Nuclear Medicine Consumption Value by Application (2021-2032)
9.3 South America Radiopharmaceutical for Nuclear Medicine Market Size by Country
- 9.3.1 South America Radiopharmaceutical for Nuclear Medicine Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Market Size by Country
- 10.3.1 Middle East & Africa Radiopharmaceutical for Nuclear Medicine Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)
- 10.3.4 UAE Radiopharmaceutical for Nuclear Medicine Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Radiopharmaceutical for Nuclear Medicine Market Drivers
11.2 Radiopharmaceutical for Nuclear Medicine Market Restraints
11.3 Radiopharmaceutical for Nuclear Medicine Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Radiopharmaceutical for Nuclear Medicine Industry Chain
12.2 Radiopharmaceutical for Nuclear Medicine Upstream Analysis
12.3 Radiopharmaceutical for Nuclear Medicine Midstream Analysis
12.4 Radiopharmaceutical for Nuclear Medicine Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Radiopharmaceutical for Nuclear Medicine market size was valued at US$ 11163 million in 2025 and is forecast to a readjusted size of US$ 20045 million by 2032 with a CAGR of 8.6% during review period.
Radiopharmaceuticals for nuclear medicine are a class of specialized drugs that combine radioactive isotopes with biologically active molecules for in vivo diagnosis and therapy. Their primary functions include imaging organs or lesions using radioactive tracers and delivering targeted radiation to tumors or diseased tissues. These drugs encompass single-photon emission computed tomography (SPECT) tracers, positron emission tomography (PET) tracers, and therapeutic radiopharmaceuticals, widely applied in oncology, cardiovascular and cerebrovascular diseases, neurological disorders, and bone diseases. The key advantages of radiopharmaceuticals lie in their high sensitivity, quantifiability, non-invasiveness, and the ability to detect diseases at early stages while enabling individualized treatment planning. With advances in nuclear imaging and radiopharmaceutical production technologies, their role in precision medicine and personalized therapy is increasingly significant.The average gross profit margin of this product is 72%.
The rapidly growing demand for precision diagnostics and personalized therapy provides significant growth opportunities for the radiopharmaceutical market. The high prevalence of cancer and cardiovascular diseases continues to drive demand for both diagnostic and therapeutic applications. The adoption of advanced imaging technologies such as PET/CT and SPECT/CT has enhanced the clinical value of radiopharmaceuticals. Meanwhile, advancements in molecularly targeted and therapeutic radiopharmaceuticals are expanding clinical indications. Government support for early disease screening and precision medicine, combined with improvements in healthcare infrastructure, further fuels market growth. The production and use of radiopharmaceuticals involve highly radioactive materials, imposing strict safety, transportation, and regulatory compliance requirements. The short half-life of radioactive isotopes creates supply chain constraints, impacting product stability and availability. Long development cycles, high investment, and technical complexity limit rapid innovation. Additionally, stringent regulatory approval processes and reimbursement policies may restrict market access and pricing, while specialized clinical expertise requirements constrain adoption. Clinical demand is shifting toward high-sensitivity, low-dose, and personalized radiopharmaceuticals, requiring more precise imaging and therapeutic planning. The integration of diagnostic and therapeutic approaches is driving growth in therapeutic radiopharmaceutical demand. Expansion into primary care and specialized centers also increases demand for small-dose, rapidly prepared, and user-friendly products. The growing emphasis on individualized precision medicine has elevated the importance of multimodal imaging and targeted therapy, generating diversified market needs. Upstream materials for radiopharmaceuticals primarily include radioactive isotopes, chemical precursors, and labeling or synthesis reagents. Radioactive isotopes are the core material, with supply constrained by reactor or accelerator capacity and isotope half-life. Chemical precursors and labeling reagents directly determine drug purity, stability, and biocompatibility. High-purity and controlled processes are critical, as any material variability can impact clinical safety and efficacy. With advancements in domestic isotope production and synthesis technologies, upstream supply is gradually being localized, though stringent quality standards and process consistency remain essential.
This report is a detailed and comprehensive analysis for global Radiopharmaceutical for Nuclear Medicine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radiopharmaceutical for Nuclear Medicine market size and forecasts, in consumption value ($ Million), 2021-2032
Global Radiopharmaceutical for Nuclear Medicine market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Radiopharmaceutical for Nuclear Medicine market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Radiopharmaceutical for Nuclear Medicine market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radiopharmaceutical for Nuclear Medicine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radiopharmaceutical for Nuclear Medicine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Lantheus Medical Imaging, Bayer, Eli Lilly, Bracco Imaging, Curium Pharma, Jubilant Pharmova, Aurobindo Pharma, Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Radiopharmaceutical for Nuclear Medicine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Diagnosis Nuclear Medicine
Therapeutic Nuclear Medicine
Market segment by Disease
Technetium-99m
Fluorine-18
Iodine-123
Iodine-131
Lutetium-177
Other
Market segment by Application
Hospital
Imaging Center
Others
Market segment by players, this report covers
Cardinal Health
GE Healthcare
Lantheus Medical Imaging
Bayer
Eli Lilly
Bracco Imaging
Curium Pharma
Jubilant Pharmova
Aurobindo Pharma
Novartis
Siemens
NTP Radioisotopes
ANSTO
Polatom
China Isotope & Radiation
Yantai Dongcheng
Seed Biological Pharmacy
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Radiopharmaceutical for Nuclear Medicine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radiopharmaceutical for Nuclear Medicine, with revenue, gross margin, and global market share of Radiopharmaceutical for Nuclear Medicine from 2021 to 2026.
Chapter 3, the Radiopharmaceutical for Nuclear Medicine competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Radiopharmaceutical for Nuclear Medicine market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Radiopharmaceutical for Nuclear Medicine.
Chapter 13, to describe Radiopharmaceutical for Nuclear Medicine research findings and conclusion.

Buy now